You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Merck
Johnson and Johnson
Medtronic
McKesson

Last Updated: June 6, 2020

DrugPatentWatch Database Preview

MYOBLOC Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for MYOBLOC

Identify potential brand extensions & biosimilar entrants

SponsorPhase
US WorldMeds LLCPhase 2/Phase 3
St Joseph University, Beirut, LebanonPhase 4
VA Connecticut Healthcare SystemPhase 1

See all MYOBLOC clinical trials

Recent Litigation for MYOBLOC

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Halozyme, Inc. v. Lee2016-12-19

See all MYOBLOC litigation

Pharmacology for MYOBLOC

Company Disclosures: US Patents for MYOBLOC

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-06-10 RX company
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for MYOBLOC

These patents were identified by searching patent claims

Supplementary Protection Certificates for MYOBLOC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
92780 Luxembourg   Start Trial PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
CA 2015 00043 Denmark   Start Trial PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
132016000025345 Italy   Start Trial PRODUCT NAME: TRASTUZUMAB PER USO SOTTOCUTANEO(HERCEPTIN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/145/002, 20130828
300822 Netherlands   Start Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Medtronic
Moodys
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.